CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
CVRx announced that Barostim will be featured in eight presentations at the HFSA Annual Scientific Meeting 2026, held Oct. 9-12 in Phoenix, including late-breaking clinical data. New analyses include the REBALANCE Registry, the largest real-world study of Barostim-treated patients to date, plus the first real-world evidence of reduced hospitalization burden in HFmrEF patients. The BENEFIT-HF trial in an expanded population will also be featured.
Key figures
- Drug Name
- Barostim
- Phase Of Trial
- BENEFIT-HF (pivotal trial in expanded population, initiated earlier this year)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.